Have you or your loved ones been diagnosed with hypertension?

You may be eligible to participate in a hypertension clinical trial.

Have you or your loved ones been diagnosed with hypertension? You may be eligible to participate in a hypertension clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Hypertension Clinical Trial in Saint-Petersburg
NCT01563731 | Phase 4 | Interventional

Have you or your loved ones been diagnosed with hypertension?

You may be eligible to participate in a hypertension clinical trial.

Have you or your loved ones been diagnosed with hypertension? You may be eligible to participate in a hypertension clinical trial.

Completed

Male & Female

65 Years +

This study has recruited 200 Participants

Stroke is one of the major causes not only of mortality, but of disease burden worldwide, because of residual disability and cognitive decline. Although blood pressure lowering has been clearly shown to be the most effective means for primary and secondary prevention of stroke, the systolic blood pressure (SBP) levels to achieve by treatment in order to optimize prevention results are unknown, and whether SBP levels lower than those usually recommended are accompanied by further or reduced benefits is undecided yet. Likewise, while low-density lipoprotein cholesterol (LDL-C) lowering by statins has been shown to be associated with primary and secondary stroke prevention, whether more intense lowering is or is not of further benefit is unknown. The Stroke in Hypertension Optimal Treatment Trial (ESH-CHL-SHOT) is a factorial 3 x 2 arm, multicenter, randomized clinical trial designed to test the hypothesis that in elderly patients at high risk of recurrent stroke (previous recent stroke or TIA) antihypertensive treatment programs aimed at reducing SBP to the usually recommended values (< 145 to 135 mmHg), to a lower goal (< 135 to 125 mmHg) or to even lower values (< 125 mmHg) will result in progressively greater reductions in recurrent stroke, incidence of cardiovascular outcomes and cognitive decline. Parallely, the preventive efficacy of more and less intense LDL-C reductions will be tested on the same outcomes.